Actively Recruiting
Management of Cisplatin-Ineligible Patients With Metastatic Bladder Cancer and The Role of Geriatric Assessments
Led by Dana-Farber Cancer Institute · Updated on 2026-02-17
180
Participants Needed
1
Research Sites
199 weeks
Total Duration
On this page
Sponsors
D
Dana-Farber Cancer Institute
Lead Sponsor
N
National Comprehensive Cancer Network
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this study is to better understand how to best treat participants with advanced bladder cancer who may not be able to tolerate all of the chemotherapy drugs that have been shown to be effective. In this study, investigators are assessing the role of the survey, the Geriatric-8, and its ability to predict outcomes in older participants undergoing cancer treatments. Additionally, investigators are evaluating the differential impact of treatments on quality of life in an older and at risk population.
CONDITIONS
Official Title
Management of Cisplatin-Ineligible Patients With Metastatic Bladder Cancer and The Role of Geriatric Assessments
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 65 years or older (no more than 20% of participants between 65-70 years old)
- Diagnosed with unresectable or metastatic bladder cancer with histologically proven urothelial carcinoma, including variant histology
- Determined to be cisplatin-ineligible by the primary oncologist
- Receiving chemotherapy with or without immunotherapy maintenance, enfortumab vedotin-pembrolizumab combination therapy, or immunotherapy alone
- Able to understand and willing to sign informed consent and complete patient-reported outcomes in English or Spanish, alone or with assistance
You will not qualify if you...
- Choosing not to undergo cancer-directed therapy
- Receiving care outside of Dana-Farber Cancer Institute or its affiliate sites
- Having advanced cognitive impairment or inability to complete surveys
- Receiving any other investigational agents for this condition, if appropriate
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02215
Actively Recruiting
Research Team
J
Joaquim Bellmunt, MD, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here